Freestone Grove Partners LP Harrow Health, Inc. Transaction History
Freestone Grove Partners LP
- $8.16 Trillion
- Q4 2024
A detailed history of Freestone Grove Partners LP transactions in Harrow Health, Inc. stock. As of the latest transaction made, Freestone Grove Partners LP holds 11,621 shares of HROW stock, worth $350,140. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,621Holding current value
$350,140% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding HROW
# of Institutions
184Shares Held
21.1MCall Options Held
679KPut Options Held
1.27M-
Opaleye Management Inc. Boston, MA3.99MShares$120 Million26.33% of portfolio
-
Black Rock Inc. New York, NY2.15MShares$64.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.87MShares$56.4 Million0.0% of portfolio
-
Private Capital Management, LLC Naples, FL1.69MShares$51.1 Million6.85% of portfolio
-
Braidwell LP Stamford, CT907KShares$27.3 Million1.7% of portfolio
About HARROW HEALTH, INC.
- Ticker HROW
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 27,070,000
- Market Cap $816M
- Description
- Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company tha...